France· FR:66978789
DOXAZOSINE SUBSTIPHARM LP 8 mg, comprimé à libération prolongée
A medicinal product containing mésilate de doxazosine, registered in France by SUBSTIPHARM, on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MÉSILATE DE DOXAZOSINE
- Manufacturer
- SUBSTIPHARM
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400921656794plaquette(s) PVC PVDC aluminium de 28 comprimé(s) en conditionnement calendaireEUR 5.69
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/18cc7e05-4f39-4233-9313-f2c282de69b1 GET /v1/drugs/18cc7e05-4f39-4233-9313-f2c282de69b1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66978789",
"date_amm": "2011-12-12",
"type_amm": "Procédure décentralisée",
"numero_ue": null,
"substance": "MÉSILATE DE DOXAZOSINE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé à libération prolongée",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about mésilate de doxazosine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.